GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX 1,931.50
-8.50 (-0.44%)
Jul 31, 2026, 4:54 PM GMT
GSK plc Financials Overview
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 33,203 | 32,667 | 31,376 | 30,328 | 29,324 | 24,696 |
Revenue Growth | 4.97% | 4.12% | 3.46% | 3.42% | 18.74% | 1.40% |
Gross Profit Gross Profit Growth | 24,402 | 23,720 | 22,531 | 21,940 | 19,917 | 16,663 |
Operating Income Operating Income Growth | 9,686 | 9,447 | 6,190 | 8,403 | 7,322 | 5,634 |
Net Income Net Income Growth | 4,821 | 5,716 | 2,575 | 4,928 | 14,956 | 4,385 |
Earnings Per Share EPS Growth | 1.18 | 1.39 | 0.62 | 1.20 | 3.66 | 1.08 |
EPS Growth | 42.63% | 123.15% | -48.12% | -67.26% | 238.48% | -24.16% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
HIV HIV Growth | 7,995 | 7,687 | 7,089 | 6,444 | 5,749 | 4,777 |
Respiratory, Immunology and Inflammation Respiratory, Immunology and Inflammation Growth | 4,068 | 3,810 | 3,299 | 3,025 | 2,609 | 2,027 |
Oncology Oncology Growth | 2,159 | 1,977 | 1,410 | 731 | 602 | 489 |
Shingles Shingles Growth | 3,752 | 3,558 | 3,364 | 3,446 | 2,958 | 1,721 |
Meningitis Meningitis Growth | 1,651 | 1,583 | 1,437 | 1,260 | 1,116 | 961 |
Influenza Influenza Growth | 317 | 303 | 408 | 504 | 714 | 679 |
Other Paediatric & Adult Vaccines Other Paediatric & Adult Vaccines Growth | 2,978 | 3,120 | 3,339 | 3,266 | 3,085 | 2,970 |
Respiratory Respiratory Growth | 6,760 | 7,068 | 7,213 | 6,825 | 6,548 | 6,048 |
Other General Medicines Other General Medicines Growth | 2,817 | 2,968 | 3,215 | 3,395 | 3,570 | 3,619 |
Revenue (Total) Revenue (Total) Growth | 33,203 | 32,667 | 31,376 | 30,328 | 29,324 | 24,696 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 3,106 | 3,421 | 3,966 | 5,280 | 8,042 | 4,965 |
Total Debt Total Debt Growth | 18,293 | 17,787 | 16,986 | 18,018 | 20,987 | 24,174 |
Net Cash (Debt) Net Cash Growth | -15,187 | -14,366 | -13,020 | -12,738 | -12,945 | -19,209 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -3.71 | -3.49 | -3.14 | -3.10 | -3.17 | -4.74 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 8,331 | 7,741 | 6,554 | 6,768 | 7,403 | 7,952 |
Capital Expenditures CapEx Growth | -1,433 | -1,348 | -1,399 | -1,314 | -1,143 | -950 |
Free Cash Flow Free Cash Flow Growth | 6,898 | 6,393 | 5,155 | 5,454 | 6,260 | 7,002 |
Free Cash Flow Growth | 7.60% | 24.02% | -5.48% | -12.88% | -10.60% | -6.04% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 73.49% | 72.61% | 71.81% | 72.34% | 67.92% | 67.47% |
Operating Margin | 29.17% | 28.92% | 19.73% | 27.71% | 24.97% | 22.81% |
Pretax Margin | 17.78% | 22.66% | 11.08% | 19.99% | 19.19% | 14.57% |
Profit Margin | 14.52% | 17.50% | 8.21% | 16.25% | 51.00% | 17.76% |
FCF Margin | 20.77% | 19.57% | 16.43% | 17.98% | 21.35% | 28.35% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.720 | 0.660 | 0.610 | 0.580 | 0.613 | 1.000 |
Dividend Per Share Growth | 7.94% | 8.20% | 5.17% | -5.31% | -38.75% | 0% |
Dividend Yield | 3.73% | 3.68% | 4.81% | 4.41% | 4.89% | 7.40% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.39 | 12.81 | 21.34 | 12.00 | 3.90 | 18.35 |
Forward PE | 10.33 | 10.18 | 8.39 | 9.38 | 10.01 | 14.00 |
P/FCF Ratio | 11.22 | 11.45 | 10.66 | 10.84 | 9.33 | 11.49 |
PS Ratio | 2.33 | 2.24 | 1.75 | 1.95 | 1.99 | 3.26 |